---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-077792"
form_type: "8-K"
ticker: "WHWK"
cik: "0001422142"
company_name: "Whitehawk Therapeutics, Inc."
filed_at: "2022-03-17T23:59:59+00:00"
generated_at: "2026-06-26T21:57:22.503994+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Aadi Bioscience reports Q4 2021 net loss of $16M; FYARRO launched Feb 2022

## Summary
- FYARRO approved Nov 2021 for malignant PEComa; launched Feb 2022; added to NCCN as preferred therapy.
- Cash and equivalents $149M as of Dec 31, 2021, expected to fund operations into 2024.
- Q4 2021 net loss $16M vs net income $7.8M in Q4 2020; full year net loss $110.7M.
- Phase 2 PRECISION 1 trial (TSC1/TSC2 alterations) open; initial data expected H1 2023.
- Operating expenses Q4 $16.9M, up from $5.7M; G&A increased due to commercial buildout.

## SEC filing metadata
- accession: 0001193125-22-077792
- form_type: 8-K
- ticker: WHWK
- cik: 0001422142
- company_name: Whitehawk Therapeutics, Inc.
- filed_at: 2022-03-17T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1422142/000119312522077792/0001193125-22-077792-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1422142/000119312522077792/d326646d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-077792
- JSON: https://secwatch.observer/filing/0001193125-22-077792.json
- Plain text: https://secwatch.observer/filing/0001193125-22-077792.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.